ClinicalTrials.gov
ClinicalTrials.gov Menu

Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00573573
Recruitment Status : Unknown
Verified March 2009 by GAAD Medical Research Institute Inc..
Recruitment status was:  Active, not recruiting
First Posted : December 14, 2007
Last Update Posted : March 24, 2009
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.

Brief Summary:
A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.

Condition or disease Intervention/treatment Phase
Hyperparathyroidism Radiation: Far Infrared Radiation Phase 1

Detailed Description:

Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.

We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.
Study Start Date : January 2007
Estimated Primary Completion Date : March 2009
Estimated Study Completion Date : July 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
1 Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.




Primary Outcome Measures :
  1. The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism. [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Persons with parathyroid disease

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00573573


Locations
Canada, Ontario
The Centre for Incurable Diseases
Toronto, Ontario, Canada, M4V 1L5
Sponsors and Collaborators
GAAD Medical Research Institute Inc.
Investigators
Study Director: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
Study Chair: Kwasi Donyina, Ph.D. GAAD Medical Research Institute Inc.

Responsible Party: Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier: NCT00573573     History of Changes
Other Study ID Numbers: GAAD-HT-CTP1
First Posted: December 14, 2007    Key Record Dates
Last Update Posted: March 24, 2009
Last Verified: March 2009

Keywords provided by GAAD Medical Research Institute Inc.:
PRIMARY HYPERPARATHYROIDISM
PARATHYROID NEOPLASMS
SECONDARY HYPERPARATHYROIDISM
HYPOCALCEMIA

Additional relevant MeSH terms:
Hyperparathyroidism
Parathyroid Diseases
Endocrine System Diseases